A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Mental Health & Behavioral Research
What is the purpose of this trial?
This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).
- Ages18 years and older
- Trial withGenentech, Inc.
- Start Date03/26/2019
- End Date12/30/2020
- Last Updated09/18/2019
- Study HIC#2000023946